Some of the biggest threats to your sight, like #WetAMD and diabetic macular edema (DME), can develop without any early warning signs. This #HealthyVisionMonth, don't wait for symptoms. A comprehensive eye exam is the best way to catch these conditions early and protect your vision for years to come. Learn more: https://bit.ly/4tD526w #EyeHealth
4D Molecular Therapeutics
Biotechnology Research
Emeryville, California 21,911 followers
Powering the Future of Genetic Medicines
About us
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and the second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.
- Website
-
http://www.4dmoleculartherapeutics.com/
External link for 4D Molecular Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Emeryville, California
- Type
- Public Company
- Founded
- 2013
- Specialties
- Gene Therapy, Adeno-Associated Virus, Biotechnology, Rare Diseases, Clinical, Lab, Clinical Trials, Science, retina, cystic fibrosis, genetic medicine, and ophthalmology
Locations
-
Primary
Get directions
5858 Horton St
455
Emeryville, California 94608, US
Employees at 4D Molecular Therapeutics
Updates
-
Ready to join a team that's continually breaking boundaries with #GeneticMedicine? We have open roles in: · Clinical Science · Clinical Operations · Supply Chain · Quality · G&A · IT · And more! Learn about our culture as one of The San Francisco Bay Area's "Top Workplaces,” and apply today: https://bit.ly/4v5v3N1 #BiotechJobs #TogetherIn4D #Hiring
-
-
This month, we’re looking forward to attending and presenting at American Society of Gene & Cell Therapy Annual Meeting and Retina World Congress 2026. We’re eager to connect with fellow experts and share our latest work in the #Retina and #GeneticMedicine field. Conference Speakers: Alisa Bowen, Brian Long, PhD, Fuad Makkouk MD, Matthew A. Cunningham, M.D., Mona Camacci, MD MS, Dhaval B. Desai #ASGCT2026 #RetinaWorldCongress
-
What an inspiring day at the San Francisco Great Strides Walk! Our team was proud to join the community and support the Cystic Fibrosis Foundation’s mission to find a cure for #CysticFibrosis (CF). #Volunteer #TogetherIn4D
-
-
Our Q1 2026 financial results are now available. During this past quarter, we continued to strengthen our strategic mission to develop innovative products that unlock the full potential of #GeneticMedicine. Learn more: https://bit.ly/3P4EWuW #Earnings #Innovation #Biopharma
-
-
We are looking forward to attending the Bank of America Securities 2026 Healthcare Conference and RBC Capital Markets 2026 Global Healthcare Conference in May. Interested in connecting? Reach out to us at: Investor.Relations@4DMT.com. https://bit.ly/4tc1nw0 #InvestorRelations #Biotech
-
-
Thank you to Dr. Allen Hu and the Cumberland Valley Retina Consultants team for their long-term commitment to 4DMT and our clinical trial programs, including 4FRONT-1 and 4FRONT-2. The PIs and study coordinators work as a highly synchronized team, focusing on clear patient identification and thorough patient education. Their collaboration and devotion create an efficient patient-centered clinical trial experience. Their efforts are advancing cutting-edge research for our #GeneticMedicine, that could meaningfully improve retinal care for patients with #WetAMD. Pictured: Mike Wissinger; Emma Melvin; Jacob Doyle; Dr. Allen Hu; Dr. Jay Berdia; Dr. Erwin Puente; Kacie Jones; Courtney Cook, Toni Sprecher; Ashley Staley
-
-
This #NationalMinorityHealthMonth, we're focusing on the health disparities that deeply impact people of color in the #CysticFibrosis (CF) community. From delayed diagnoses to significant barriers in care and treatment, the health experience is often riddled with difficulties. We are committed to pioneering a #GeneticMedicine that has the potential to help people with CF, regardless of their specific mutation. Learn more: https://bit.ly/3QaQRHS
-
We’re thrilled to highlight the exceptional team at Tyler Retina Consultants, led by Samuel Minaker M.D., MSc., as they make significant contributions to advancing the 4FRONT-2 trial of our #GeneticMedicine for patients with #WetAMD. For Dr. Minaker's patients in East Texas, many of whom travel over 100 miles for anti-VEGF injections, the burden of continuous treatment is immense. Unpredictable weather and caregiver burden can cause patients to miss or postpone visits, leading to poorer outcomes. Durable therapies could greatly improve patient results in rural areas. His team is optimistic that our innovative genetic medicine could create a paradigm shift with meaningful outcomes for patients. Pictured: Samuel Minaker, Harshi Bains M.D., Ph.D., Amar Patel M.D., Melissa Long, Fatima Martinez, Rebecca Bravo, Lajia Taylor, Sara Mott, Bobby Grounds, Courtney Roseberry, Alyson Ortiz, Sellena Gerungan, Mariana Zuniga, Brandy Luce, Fabiola Oviedo Not Pictured: Gabriela Lahaie Luna M.D., Abigal Betancourt
-
-
Women are disproportionately affected by vision loss. This disparity is especially prominent in diseases like #WetAMD, where women face a higher risk of rapid and severe vision loss. This Women's Eye Health & Safety Month, we believe addressing this disparity requires a dual focus. We must increase awareness for screening today while pioneering the science that will define treatment tomorrow. We are committed to that future, developing potential new #GeneticMedicines for retinal vascular diseases like #WetAMD. #WomensHealth